Biogen reports 10 more Tysabri PML cases including four deaths
This article was originally published in Scrip
Executive Summary
Biogen Idec has confirmed that there have been 10 more cases of the rare brain viral infection, progressive multifocal leukoencephalopathy (PML), among multiple sclerosis patients taking Tysabri (natalizumab), a medication that it co-markets with Elan, bringing the total number of confirmed cases to 95 as of 2 February.